Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) shares traded up 3.5% on Friday . The company traded as high as $4.20 and last traded at $4.14, with a volume of 77,206 shares changing hands. The stock had previously closed at $4.00.

Separately, Zacks Investment Research raised Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday.

The firm’s 50-day moving average price is $3.86 and its 200-day moving average price is $4.29. The stock’s market cap is $54.15 million.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last released its quarterly earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by $0.16. The firm earned $4.40 million during the quarter, compared to analysts’ expectations of $3.24 million. On average, analysts forecast that Imprimis Pharmaceuticals Inc. will post ($0.94) EPS for the current year.

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.